Large randomized trials, such as those based on the SPRINT analysis, showed that targeting lower systolic BP (<120 mmHg versus <140 mmHg) reduced the risk of MCI or dementia diagnoses, including in patients with elevated cardiac biomarkers (High-Sensitivity Troponin T, NT-proBNP) [23]. This evidence concerns the gene NPPB and dementia.